TEVA PHARMACEUTICAL INDUSTRIES LTD Form 6-K June 24, 2008

#### FORM 6-K

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Report of Foreign Private Issuer** 

Pursuant to Rule 13a 16 or 15d 16 under the Securities Exchange Act of 1934

For the month of June 2008

Commission File Number \_\_\_\_\_\_0-16174

\_\_1\_\_

| Teva Pharmaceutical Industries Limited  |  |  |  |  |
|---|--|--|--|--|
| (Translation of registrant's name into English)   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
| 5 Basel Street, P.O. Box 3190   |  |  |  |  |
| Petach Tikva 49131 Israel   |  |  |  |  |
|   |  |  |  |  |
| (Address of principal executive offices)  |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
| Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F       |  |  |  |  |
|   |  |  |  |  |
| Form 20-F Form 40-F   |  |  |  |  |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule            |  |  |  |  |
| 101(b)(1):  |  |  |  |  |
|   |  |  |  |  |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): |  |  |  |  |
|   |  |  |  |  |
| Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby          |  |  |  |  |
| furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934           |  |  |  |  |
|   |  |  |  |  |
| Yes NoX   |  |  |  |  |
| If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b):          |  |  |  |  |
| 82  |  |  |  |  |

| Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 6-K |
|---|
|---|

| Teva Pharmaceutical Industries Ltd. |                               | Web Site: www.tevapharm.com                               |                                    |  |
|-------------------------------------|-------------------------------|---|------------------------------------|--|
| Contact:                            | Elana Holzman<br>Kevin Mannix | Teva Pharmaceutical Industries Ltd.<br>Teva North America | 972 (3) 926-7554<br>(215) 591-8912 |  |

#### WEBCAST ALERT - FOR IMMEDIATE RELEASE

# TEVA TO PRESENT AT THE PIPER JAFFRAY THIRD ANNUAL EUROPE CONFERENCE

**Jerusalem, Israel, June 24, 2008** - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Piper Jaffray Third Annual Europe Conference in London. Dan Suesskind, Chief Financial Officer, will present on Wednesday, June 25, 2008.

What: Teva Presentation at the Piper Jaffray Third Annual Europe Conference in London.

Who: Dan Suesskind, Chief Financial Officer.

| When: Wednesday, June 25, 2008 at 9:00 a.m. (local time).  |
|--|
| Where: www.tevapharm.com or www.piperjaffray.com/europe2008  |
| <b>How:</b> Live over the Internet log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.   |
| About Teva   |
| Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe. |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
| Teva Pharmaceutical Industries Ltd. Web Site: <a href="www.tevapharm.com">www.tevapharm.com</a>  |
|  |

## ${\bf Edgar\ Filing:\ TEVA\ PHARMACEUTICAL\ INDUSTRIES\ LTD\ -\ Form\ 6-K}$

#### **SIGNATURES**

| Pursuant to the requirements of the Securities Exchange Act of 1934 | , the registrant has duly caused this report to be |
|---|--|
| signed on its behalf by the undersigned, thereunto duly authorized. |  |

#### TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

By: /s/ Dan Suesskind

Name: Dan Suesskind

Title: Chief Financial Officer

Date: June 24, 2008

\_\_2\_\_